Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modification of hemoglobin by ninhydrin

G Kokkini, V J Stevens, C M Peterson

    Blood
    |October 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Is There More than One Erythropoietin Receptor? Can the Hematopoietic Effects of EPO Be Dissociated from the Organ-Protective Effects by Carbamylated Erythropoietin?: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.

    Journal of the American Society of Nephrology : JASN·2023
    Same author

    The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's.

    Journal of internal medicine·2012
    Same author

    The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

    Journal of internal medicine·2010
    Same author

    Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

    Journal of internal medicine·2008
    Same author

    Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

    Kidney international·2006
    Same author

    Erythropoietin: a candidate compound for neuroprotection in schizophrenia.

    Molecular psychiatry·2003
    Same journal

    Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

    Blood·2026
    Same journal

    Identifying steroid-refractory aGVHD before it happens.

    Blood·2026
    Same journal

    ELISA-negative HIT: antibody recognition and relevance.

    Blood·2026
    Same journal

    EBV and immunodeficiency: the odd couple drawn to the brain.

    Blood·2026
    Same journal

    A bone to pick with ferric carboxymaltose.

    Blood·2026
    Same journal

    A step toward streamlining HIT diagnosis.

    Blood·2026
    See all related articles

    Ninhydrin modifies hemoglobin in vitro, altering its structure and increasing oxygen affinity. This study suggests carbonyl compounds can specifically modify hemoglobin variants for therapeutic potential.

    Area of Science:

    • Biochemistry
    • Hematology
    • Chemical Biology

    Background:

    • The Strecker degradation reaction offers a potential method for in vitro hemoglobin modification.
    • Understanding hemoglobin structure-function relationships is crucial for treating hemoglobinopathies.

    Purpose of the Study:

    • To evaluate the Strecker degradation reaction using ninhydrin for hemoglobin modification.
    • To characterize the structural and functional changes in hemoglobin induced by ninhydrin.

    Main Methods:

    • Incubation of hemoglobin and red blood cells with ninhydrin under physiological conditions.
    • Analysis using isoelectric focusing, electrophoresis, and amino acid analysis.
    • Measurement of hemoglobin oxygen affinity.

    Related Experiment Videos

    Main Results:

    • Ninhydrin modified hemoglobin, creating new bands with more negative isoelectric points.
    • Both alpha and beta chains were modified, with distinct species identified for each.
    • Amino acid analysis indicated deamination of valine, lysine, and arginine residues.
    • Hemoglobin oxygen affinity increased with higher ninhydrin concentrations.

    Conclusions:

    • Ninhydrin effectively modifies hemoglobin structure and function in vitro.
    • Carbonyl compounds represent a class of agents capable of specific hemoglobin modification.
    • Potential applications in developing treatments for hemoglobin variants.